ViaCyte nabs $80 mln Series D


San Diego-based ViaCyte Inc, a privately-held clinical stage regenerative medicine company, has secured $80 million in Series D financing. The investors included Bain Capital Life Sciences, TPG and RA Capital Management.

Source: Press Release